Press Releases

Epizyme To Participate in H.C. Wainwright Global Investment Conference

May 17, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2022-- Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference.

A pre-recorded fireside chat will be available to play on demand starting at 7:00am EST on Tuesday, May 24, 2022. It can be found in the investor section of the Company’s website at www.epizyme.com and will be archived after 60 days following the presentation.

About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit www.epizyme.com.

Media: Erin Graves
media@epizyme.com
(617) 500-0615

Investors: Caitlin Stern
cstern@realchemistry.com

Source: Epizyme, Inc.